Identification of a novel marker associated with risk for delayed chemotherapy-induced vomiting-Reference-Cited by-同舟云学术

Identification of a novel marker associated with risk for delayed chemotherapy-induced vomiting

Published:2012-02-14 Issue:11 Volume:20 Page:2803-2809
ISSN:0941-4355
Container-title:Supportive Care in Cancer
language:en
Short-container-title:Support Care Cancer

Author:

Higa Gerald M.,Auber Miklos L.,Hobbs Gerry

Publisher

Springer Science and Business Media LLC

Subject

Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00520-012-1402-2.pdf

Reference26 articles.

1. American Society of Clinical Oncology (1996) Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. J Clin Oncol 14:671–679

2. Wang J, Zhao Z, Barber B, Sherrill B, Peeters M, Wiezorek J (2011) A Q-TWiST analysis comparing panitumumab plus best supportive care (BSC) with BSC alone in patients with wild-type KRAS metastatic colorectal cancer. Br J Cancer 104:1848–1853

3. Ahmed N, Ahmedzai S, Vora V, Hillam S, Paz S (2004) Supportive care for patients with gastrointestinal cancer. Cochrane Database Syst Rev 3:CD003445

4. Hesketh PJ, Aapro M, Street JC, Carides AD (2010) Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy. Support Care Cancer 18:1171–1177

5. Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R, Chawla SP, Carides AD, Ianus J, Elmer ME, Evans JK, Beck K, Reines S, Horgan KJ (2003) The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin—the Aprepitant Protocol 052 Study Group. J Clin Oncol 15:4112–4119

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An assessment of the effects of neurokinin₁ receptor antagonism against nausea and vomiting: Relative efficacy, sites of action and lessons for future drug development;British Journal of Clinical Pharmacology;2023-08-17

2. Elevated serum substance P level as a predictive marker for moderately emetogenic chemotherapy‐induced nausea and vomiting: A prospective cohort study;Cancer Medicine;2020-12-27

4. Plasma substance P concentrations in patients undergoing general anesthesia: an objective marker associated with postoperative nausea and vomiting;JA Clinical Reports;2016-06-02

5. The Physiology and Pharmacology of Nausea and Vomiting Induced by Anticancer Chemotherapy in Humans;Management of Chemotherapy-Induced Nausea and Vomiting;2016